Subscribe
shutterstock_775583896_meletios_verras
Meletios Verras / Shutterstock.com
5 September 2019Big PharmaSaman Javed

LSIPR webinar: CAR-T trends show increased filing for narrower tech, says HGF partner

CAR-T cells have achieved hugely-positive outcomes in treating forms of cancer that are otherwise difficult to treat.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Novartis signs deal to bring CAR T therapy to China
1 October 2018   Novartis has teamed up with a clinical-stage biopharmaceutical firm in efforts to bring the Swiss company’s proprietary cancer treatment to patients in China.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Asia
Novartis signs deal to bring CAR T therapy to China
1 October 2018   Novartis has teamed up with a clinical-stage biopharmaceutical firm in efforts to bring the Swiss company’s proprietary cancer treatment to patients in China.

More on this story

Asia
Novartis signs deal to bring CAR T therapy to China
1 October 2018   Novartis has teamed up with a clinical-stage biopharmaceutical firm in efforts to bring the Swiss company’s proprietary cancer treatment to patients in China.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team